Navidea Biopharmaceuticals Inc (NAVB)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SUPPLIES
SIC:
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
CEO:
Mike M. Goldberg
Employees:
14
4995 BRADENTON AVENUE, SUITE 240, DUBLIN, OH 43017
6147937500

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The company operates through the following segments: Diagnostics, Therapeutics and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Data derived from most recent annual or quarterly report
Market Cap 22.163 Million Shares Outstanding30.36 Million Avg 30-day Volume 40.277 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.19
Price to Revenue58.8172 Debt to Equity-0.054 EBITDA-11.686 Million
Price to Book Value0.0 Operating Margin-2871.6585 Enterprise Value23.174 Million
Current Ratio0.474 EPS Growth0.071 Quick Ratio0.248
1 Yr BETA 0.2142 52-week High/Low 1.96 / 0.56 Profit Margin-2881.7988
Operating Cash Flow Growth5.5739 Altman Z-Score-154.2413 Free Cash Flow to Firm -4.887 Million
View SEC Filings from NAVB instead.

View recent insider trading info

Funds Holding NAVB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NAVB BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-20:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.02: Unregistered Sales of Equity Securities
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-16:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-09:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-26:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CAPPELLO ALEXANDER L

    • Director
    53,977 2022-05-31 9

    SCOTT JOHN K JR.

    • Director
    • 10% Owner
    8,109,294 2022-05-31 7

    WITTER MALCOLM G

    • Director
    151,388 2022-05-31 10

    BHALLA AMIT

    • Director
    58,068 2022-05-31 8

    ROSOL MICHAEL STANLEY CHIEF MEDICAL OFFICER

    • Officer
    21,391 2022-01-14 3

    FARB THOMAS F

    • Director
    33,425 2021-11-15 2

    WINKLER AGNIESZKA

    • Director
    33,600 2021-11-15 2

    MIKHAIL MICHEL CHIEF REGULATORY OFFICER

    • Officer
    75,000 2021-11-15 2

    BRUCK CLAUDINE

    • Director
    16,519 2021-06-30 0

    ROUAN SARAH KATHRYN

    • Director
    18,242 2021-06-30 0

    LATKIN JED CEO, COO & CFO

    • Officer
    • Director
    10,600 2021-02-15 0

    KAUFMAN JOEL H. CHIEF BUSINESS OFFICER

    • Officer
    9,648 2021-02-15 0

    RICE YEHUDA MICHAEL

    • Director
    12,500 2021-01-13 0

    CUTLER ADAM D.

    • Director
    10,000 2021-01-13 0

    COPE FREDERICK O SVP & CSO

    • Officer
    585,052 2018-06-29 0

    ROWINSKY ERIC K

    • Director
    341,446 2018-02-20 0

    GREENE MARK I

    • Director
    157,244 2018-02-20 0

    FIORINO ANTHONY S.

    • Director
    78,000 2017-06-30 0

    REGAN WILLIAM J. SVP & CCO

    • Officer
    172,977 2017-06-29 0

    GOLDBERG MICHAEL M PRESIDENT & CEO

    5,921,023 2017-05-16 0

    KLIMA THOMAS J SVP & CHIEF COMMERCIAL OFFICER

    • Officer
    51,935 2017-02-06 0

    TROUP GORDON A

    • Director
    No longer subject to file 2016-04-20 0

    LARSON BRENT L EVP, CFO, TREAS & SEC'Y

    • Officer
    0 2016-02-25 0

    GUETH ANTON

    • Director
    38,918 2016-01-06 0

    FORD BRENDAN A

    • Director
    239,950 2015-07-31 0

    KARSEN PERRY A

    • Director
    No longer subject to file 2015-07-16 0

    DRAKE PETER F

    • Director
    No longer subject to file 2015-07-16 0

    TOMBLYN MICHAEL SVP, CHIEF MED. OFFICER

    • Officer
    100,000 2015-07-02 0

    TULIP THOMAS H. CHIEF BUS. OFFICER

    • Officer
    77,966 2015-03-26 0

    GONZALEZ RICARDO J CHIEF EXECUTIVE OFFICER

    • Officer
    0 2014-10-13 0

    NORDLICHT MARK

    PLATINUM MANAGEMENT (NY) LLC

    LANDESMAN URI

    PLATINUM LIQUID OPPORTUNITY MANAGEMENT (NY) LLC

    PLATINUM PARTNERS LIQUID OPPORTUNITY MASTER FUND L.P.

    PLATINUM PARTNERS VALUE ARBITRAGE FUND, LP

    PLATINUM-MONTAUR LIFE SCIENCES, LLC

    • 10% Owner
    No longer subject to file 2014-09-02 0

    NORDLICHT MARK

    PLATINUM MANAGEMENT (NY) LLC

    PLATINUM PARTNERS VALUE ARBITRAGE FUND, LP

    LANDESMAN URI

    PLATINUM LIQUID OPPORTUNITY MANAGEMENT (NY) LLC

    PLATINUM PARTNERS LIQUID OPPORTUNITY MASTER FUND L.P.

    • 10% Owner
    15,106,431 2014-08-12 0

    PYKETT MARK JEROME

    • Director
    318,505 2014-06-01 0

    REININGER CORNELIA SVP & CHIEF MEDICAL OFFICER

    • Officer
    0 2014-01-28 0

    PLATINUM-MONTAUR LIFE SCIENCES, LLC

    PLATINUM PARTNERS VALUE ARBITRAGE FUND, LP

    • 10% Owner
    • SEE EXPLANATION OF RESPONSES
    10,073,375 2013-11-13 0

    BROWN RODGER A VICE PRESIDENT

    • Officer
    123,027 2013-03-13 0

    JONES JESS

    • Director
    29,250 2013-02-21 0

    BUPP DAVID C

    • Director
    2,843,130 2011-11-17 0

    ASCHINGER CARL J JR

    • Director
    158,620 2011-05-27 0

    BLAIR ANTHONY K VP-MANUFACTURING & OPERATIONS

    • Officer
    38,544 2011-05-27 0

    RASH DOUGLAS L VICE PRESIDENT, MARKETING

    • Officer
    0 2010-12-21 0

    JOHNSON OWEN E

    • Director
    70,000 2010-12-08 0

    MILLER FRED B

    • Director
    141,000 2010-06-16 0

    AVITAL REUVEN

    • Director
    289,256 2010-03-16 0

    WHITLEY J FRANK

    • Director
    61,500 2009-12-30 0

    BLAND KIRBY I

    • Director
    0 2009-01-05 0

    BOSCH CARL M VP - INSTRUMENT DEVELOPMENT

    • Officer
    50,000 2006-12-15 0

    KREVANS JULIUS R

    • Director
    20,000 2006-12-15 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    CAPPELLO ALEXANDER L - Director

    2022-06-01 16:33:30 -0400 2022-05-31 A 2,500 a 53,977 direct -3.125 -15.625 0.0 1 -15.625 6

    WITTER MALCOLM G - Director

    2022-06-01 16:37:05 -0400 2022-05-31 A 2,500 a 151,388 direct -3.125 -15.625 0.0 1 -15.625 6

    SCOTT JOHN K JR. - Director - > 10% Owner

    2022-06-01 16:35:21 -0400 2022-05-31 A 2,500 a 8,095,895 direct -3.125 -15.625 0.0 1 -15.625 6

    BHALLA AMIT - Director

    2022-06-01 16:32:14 -0400 2022-05-31 A 2,500 a 58,068 direct -3.125 -15.625 0.0 1 -15.625 6

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 22:15:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 21:45:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 21:15:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 20:45:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 20:15:04 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 19:45:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 19:15:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 18:45:04 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 18:15:04 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 17:45:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 17:15:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 16:45:04 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 16:15:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 15:45:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 15:15:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 14:45:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 14:15:03 UTC -8.1501 9.7201 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 13:45:03 UTC -8.3144 9.8844 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 13:15:03 UTC -8.3144 9.8844 200000
    NAVIDEA BIOPHARMACEUTICALS I NAVB 2022-06-30 12:45:03 UTC -8.3144 9.8844 200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments